Antibody against insoluble fibrin
With the intention of providing an antibody which does not bind to fibrinogen and which has a high affinity for and a high specificity to insoluble fibrin, it is found that a site comprising the amino acids at positions 231 to 246 of the fibrinogen Bβ chain and a site comprising the amino acids at positions 232 to 246 of the fibrinogen γ chain are bound to each other in a fibrinogen molecule. Further, it is shown that when fibrinogen is converted to insoluble fibrin, the binding is released, and these sites are exposed. It is also found that antibodies obtained by immunization with these sites do not bind to fibrinogen and have high affinity for and high specificity to insoluble fibrin.
1. An antibody which binds to insoluble fibrin and which does not bind to fibrinogen, wherein the antibody binds to a site shown in SEQ ID NO: 1 or a site shown in SEQ ID NO: 2.
2. The antibody according to claim 1 , comprising:
a light chain variable region comprising the amino acid sequences shown in SEQ ID NOs: 4 to 6; and
a heavy chain variable region comprising the amino acid sequences shown in SEQ ID NOs: 8 to 10.
3. The antibody according to claim 1 , comprising:
a light chain variable region comprising the amino acid sequences shown in SEQ ID NOs: 12 to 14; and
a heavy chain variable region comprising the amino acid sequences shown in SEQ ID NOs: 16 to 18.
4. The antibody according to claim 1 , comprising:
a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 3; and
a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 7.
5. The antibody according to claim 1 , comprising:
a light chain variable region comprising the amino acid sequence shown in SEQ ID NO: 11; and
a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO: 15.
6. A composition comprising the antibody according to claim 1 and a pharmaceutically acceptable carrier that allows for immunological measurement.
7. A composition comprising the antibody according to claim 1 and a pharmaceutically acceptable carrier that allows for diagnosing a disease characterized by the presence of a thrombus.
8. A composition comprising the antibody according to claim 1 and a pharmaceutically acceptable carrier that allows for visualizing a thrombus.
9. A method for detecting insoluble fibrin in a sample, comprising the steps of:
(a) bringing the antibody according to claim 1 into contact with the sample; and
(b) detecting whether or not the antibody is bound to insoluble fibrin in the sample.
10. A method for diagnosing a disease characterized by the presence of a thrombus in a subject, comprising the steps of:
(a) bringing the antibody according to claim 1 into contact with a sample obtained from the subject; and
(b) detecting whether or not the antibody is bound to insoluble fibrin in the sample.
11. A conjugate, comprising:
the antibody according to claim 1 ; and
an antitumor part.
12. A method for diagnosing a disease characterized by the presence of thrombus, comprising the steps of:
administrating the antibody according to claim 1 labeled with a label to a subject;
visualizing a position of a thrombus in the subject on the basis of the label of the antibody; and
diagnosing whether the subject has developed the disease characterized by the presence of thrombus or has a risk of developing it at the visualized position.